Microscopic image showing a CAR T cell killing a cancer cell

Automated, standardized and easily scalable

The CliniMACS Prodigy® CAR T Cell Process – A complete manufacturing solution

Microscopic image showing a CAR T cell killing a cancer cell

The CliniMACS Prodigy® T Cell Transduction Process provides a unique all-in-one solution for the complex manufacturing process for engineered T cells. While manual protocols are risky and variable, our automated and standardized processes guarantee robust and consistent CAR T cell products, with significantly reduced operator hands-on time.

All manufacturing protocols are customizable by you or with the help of our experts. Verified production processes can be easily transferred to any number of CliniMACS Prodigy Instruments or manufacturing sites and treatment centers – anywhere on the globe. Besides that, the closed-system approach allows for parallel manufacturing with multiple instruments in one room, reducing space and costs.

For complete regulatory notes click here.

The CliniMACS Prodigy CAR T Cell Process – A complete manufacturing solution

Watch a full CAR T cell manufacturing run on the CliniMACS Prodigy in time-lapse. After the installation of the tubing set and connection of your starting material, cells are being processed fully automated and safe with minimal involvement from the user. The instrument is able to perform cell enrichment, activation, genetic manipulation, and expansion.

Learn how the CliniMACS Prodigy can support your CAR T cell manufacturing vision

Video

Semi-automated CAR T cell manufacturing: focus on the UCL CAR T cell program

Watch this presentation given by Claire Roddie, M.D., Ph.D., (UCL Cancer Institute, London, UK) at EBMT 2020 Virtual. She demonstrates how semi-automated, closed cell manufacturing processes were incorporated into the UCL CAR T cell program.

Video

Webinar by MACS Academy: Simplifying GMP CAR T and CAR NK cell therapy manufacturing processes

Upscaling and streamlining manufacturing processes are key to ensure future successes in the clinic. In this webinar, we introduce and discuss our solutions for generating gene-modified CAR T and CAR NK cells in a standardized and fully automated fashion, with academic and industry end user panelists.

Learn more about:

  • Translation and upscaling of CAR T and CAR NK cell manufacturing
  • Harnessing closed system automation for CAR T and CAR NK cell processes
  • How to simplify CAR T cell production including IPC/QC solutions

Are you interested in automated and GMP-compliant manufacturing of engineered T cells?

  • Please fill out this form and a representative of Miltenyi Biotec will contact you to complete your request.

  • Contact information

  • Questions / Comments

  • *mandatory field

  • The Miltenyi Company Group collects and processes data submitted herein in accordance with Miltenyi's Privacy Statement.

  • 1/1